RxDoctor Payments DataLook up a doctor →

Francis Worden, MD

Medical Oncology · Ann Arbor, MINPI 1700962677

Payments from drug & device makers

$4,244,702in general payments, 2019–2025

Across 293 payments — averaging $14,487 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.6M
  • Eli Lilly$1.2M
  • Pfizer$905K
  • E.r. Squibb & Sons, L.L.C.$114K
  • Coherus Oncology, Inc.$75K
  • Regeneron$65K
  • plus $244K from 10 others
$3,173in research payments, 2019–2025

Across 19 payments — averaging $167.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$3K
  • Corcept Therapeutics$40

What the payments were for

  • Consulting fees$109,74777%
  • Speaking & faculty fees$16,41512%
  • Travel & lodging$12,2809%
  • Food & beverage$3,6803%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,244,702 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in Michigan.

See all medical oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$38,230
Medicare patients
120
Services billed
595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VitrakviLarotrectinib Sulfate17$595,844
LenvimaLenvatinib Mesylate21$500,842
ErivedgeVismodegib24$315,710
TafinlarDabrafenib Mesylate13$143,484
EliquisApixaban24$24,324
Buprenorphine19$3,204
Levothyroxine Sodium131$1,646
SynthroidLevothyroxine Sodium19$1,474
Prochlorperazine Maleate50$879
Ondansetron OdtOndansetron46$753
Calcitriol19$660
Hydrocortisone15$500
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$491
Oxycodone Hcl18$484
Morphine Sulfate ErMorphine Sulfate11$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerVitrakvi$28,422$595,84417 claims
Eisai Inc.Lenvima$51,305$500,84221 claims
PfizerEliquis$904,947$24,32424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 170 medical oncology providers in Michigan.

Other medical oncology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →